AGL 38.50 Increased By ▲ 0.93 (2.48%)
AIRLINK 132.00 Decreased By ▼ -0.50 (-0.38%)
BOP 5.60 Decreased By ▼ -0.04 (-0.71%)
CNERGY 3.84 Increased By ▲ 0.07 (1.86%)
DCL 8.67 Decreased By ▼ -0.20 (-2.25%)
DFML 40.80 Decreased By ▼ -0.20 (-0.49%)
DGKC 88.71 Decreased By ▼ -1.45 (-1.61%)
FCCL 35.20 Increased By ▲ 0.12 (0.34%)
FFBL 66.49 Decreased By ▼ -0.01 (-0.02%)
FFL 10.47 Increased By ▲ 0.32 (3.15%)
HUBC 109.50 Increased By ▲ 3.10 (2.91%)
HUMNL 14.66 Increased By ▲ 1.26 (9.4%)
KEL 4.81 Decreased By ▼ -0.05 (-1.03%)
KOSM 7.07 Increased By ▲ 0.22 (3.21%)
MLCF 42.50 Increased By ▲ 0.70 (1.67%)
NBP 59.47 Increased By ▲ 0.89 (1.52%)
OGDC 184.00 Increased By ▲ 2.75 (1.52%)
PAEL 25.60 Decreased By ▼ -0.10 (-0.39%)
PIBTL 5.90 Increased By ▲ 0.07 (1.2%)
PPL 147.50 Decreased By ▼ -0.90 (-0.61%)
PRL 23.51 Increased By ▲ 0.29 (1.25%)
PTC 16.45 Increased By ▲ 1.21 (7.94%)
SEARL 69.28 Increased By ▲ 0.49 (0.71%)
TELE 7.25 Increased By ▲ 0.01 (0.14%)
TOMCL 35.80 Decreased By ▼ -0.20 (-0.56%)
TPLP 7.55 Increased By ▲ 0.15 (2.03%)
TREET 14.19 Decreased By ▼ -0.05 (-0.35%)
TRG 50.80 Decreased By ▼ -0.05 (-0.1%)
UNITY 26.83 Increased By ▲ 0.43 (1.63%)
WTL 1.22 Increased By ▲ 0.01 (0.83%)
BR100 9,820 Increased By 52.7 (0.54%)
BR30 29,792 Increased By 391.6 (1.33%)
KSE100 92,366 Increased By 427.5 (0.47%)
KSE30 28,825 Increased By 81 (0.28%)
Pakistan

Govt allows Russia's Sputnik V COVID vaccine for 'emergency use'

  • Russia’s Sputnik V Covid-19 vaccine has become the third to be approved for emergency use in the country
  • The double dose of Sputnik V in Pakistan would cost double the rates at which it is available in India
Published January 24, 2021

(Karachi) As part of measures to protect the population from coronavirus, the government has given approval for Russian developed Sputnik V vaccine under “emergency use authorisation”, local media reported. A local pharmaceutical company has been assigned the task to import and distribute the vaccine.

As per details, Russia’s Sputnik V Covid-19 vaccine has become the third to be approved for emergency use in the country. The double dose of Sputnik V in Pakistan would cost double the rates at which it is available in India.

Reportedly, the approval for the vaccine has been given in a meeting of the registration board of the Drug Regulatory Authority of Pakistan (Drap).

DRAP officials said a committee of experts comprising top infectious diseases experts and pathologists for the evaluation of clinical trials data for registration of COVID-19 vaccines on January 21, 2020 recommended the granting of Emergency Use Authorization for Sputnik-V vaccine in Pakistan.

Drap has already authorised Oxford University-AstraZeneca Covid-19 vaccine for emergency use in Pakistan and Chinese state-owned firm Sinopharm’s Covid-19 vaccine for emergency use.

Earlier, as struggle to get coronavirus vaccine gained momentum globally, Russia offered to supply its Sputnik V COVID-19 vaccine to Pakistan.

The Ministry of Foreign Affairs received a letter to this effect along with data on the vaccine’s clinical research and trials from the Russian Embassy in Islamabad. The Foreign Ministry sent the vaccine offer to the National Health Services (NHS) for further process.

Vaccine developed by Russia proved to be 92 percent effective in preventing coronavirus, the interim results showed. Russia registered Sputnik V for public use in August, the first country to do so, though the approval came before the start of the large-scale trial in September.

The Phase III trial of the shot developed by the Gamaleya Institute took place in 29 clinics across Moscow and involved 40,000 volunteers in total. The chances of contracting COVID-19 were 92% lower among people vaccinated with Sputnik V, the Russian Direct Investment Fund stated.

Comments

Comments are closed.